Advanced Renal Cell Carcinoma
2 papers
- Human trial1
- Humans1
Trial sponsors
Company2 trialsPhase 3794 people
Company1 trialPhase 2/3265 people
Company1 trialPhase 2152 people
Company1 trialPhase 218 people
Company1 trialPhase 216 people
1 trialPhase 241 people
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
1 trialPhase 1/240 people
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
1 trialPhase 1/240 people
Latest
2 in 12 monthsResearch Square
Lipid-Lowering Therapy Use and Survival Outcomes in Advanced Renal Cell Carcinoma Treated with Toripalimab Plus Axitinib or Sunitinib: A Post Hoc Analysis of the Phase III RENOTORCH Trial
Preprint: cohort study of 421 peopleKidney
Journal for Immunotherapy of Cancer
Aging is associated with the outcomes of immune checkpoint blockade in renal cell carcinoma
Meta-analysis of randomised trialsRenal cell carcinoma
The Lancet Oncology
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Randomised trial in 658 peopleKidney